相关实验视频

Updated: May 22, 2025

A Mass Spectrometry-Based Approach to Identify Phosphoprotein Phosphatases and their Interactors

A Mass Spectrometry-Based Approach to Identify Phosphoprotein Phosphatases and their Interactors

Published on: April 29, 2022

蛋白组学确定了白血病细胞中PAK抑制剂敏感性的决定因素

Pedro Casado¹, Santiago Marfa², Marym M Hadi²

¹Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, EC1M6BQ, UK. p.m.casado-irquierdo@qmul.ac.uk.

Cell communication and signaling : CCS

|March 14, 2025

概括

P21激活激酶抑制剂 (PAKi) 显示出治疗急性髓性白血病 (AML) 的前景. 这项研究揭示了PF-3758309通过抑制关键途径有效向AML细胞,并确定PHF2酸化作为个性化治疗的预测生物标志物.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

P21激活激酶 (PAK) 在癌症信号传递中至关重要,并且在抗癌治疗中被PAK抑制剂 (PAKi) 准.
对PAKi机制的有限理解阻碍了临床应用,需要进一步研究急性髓性白血病 (AML).

研究的目的:

在AML模型中描述对PAK抑制剂 (PF-3758309,FRAX-486,IPA-3) 的功能和分子反应.
识别AML中PAKI影响的生物化学途径,并在患者样本中发现治疗反应的决定因素.

主要方法:

在AML细胞系和初级患者细胞中集成的光蛋白质组学,蛋白质组学和基因依赖数据.
评估了PAKi对细胞周期,增殖,分化和亡的影响.
利用蛋白质组学数据的机器学习来预测ex vivo反应,并在AML患者样本中识别生物标志物.

主要成果:

PAK1激活预测AML的预后不佳;PF-3758309在减少扩散和诱导亡方面表现出显著的有效性.
PF-3758309抑制了PAK,AMPK和PKCA,降低了c-MYC活性,并影响了相关AML亚型中的FLT3通路.
机器学习模型准确地预测了PF-3758309的反应,确定了PHF2酸化在Ser705作为关键生物标志物.

结论:

定义了AML细胞对PF-3758309.9的全面蛋白质,分子和功能反应.
建议使用基于已识别的生物标志物的PAK抑制剂来个性化AML治疗策略的途径.

关键词:

急性髓性白血病的生物标志物癌症癌症癌症癌症激酶抑制剂的使用氨酸脱甲基酶 PHF2 氨酸脱甲基酶 PHF2 机器学习是机器学习.PAK 抑制剂是一种抑制剂.PF-3758309 是一个非常有价值的公司.酸蛋白组学酸蛋白组学酸蛋白组学蛋白质组学是指蛋白质组学.目标疗法目标疗法

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Amplifying Signals via Enzymatic Cascade

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...